CXCR4 and neoplasm: Additionally, Ling et al (15) reported that the CXCR4 antagonist, AMD3465, inhibits the growth and migration of breast cancer by partially blocking signal transducer and activator of transcription 3 signaling, which has an impact on tumor and immune cells in the internal tumor environment.